Loading fund…
Loading fund…
| Returns | 1D | 1M | 3M | YTD | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|
| Total return | ▼ −0.1% | ▼ −3.9% | ▼ −11.6% | ▲ +9.4% | ▲ +25.5% | ▲ +136.7% | ▲ +26.9% | ▲ +145.0% |
| Peer average | ▲ +1.2% | ▲ +4.5% | ▲ +9.5% | ▲ +22.6% | ▲ +30.8% | ▲ +76.1% | ▲ +30.8% | — |
| S&P 500 · VOO | ▼ −0.4% | ▲ +0.9% | ▲ +3.3% | ▲ +13.8% | ▲ +13.3% | ▲ +88.8% | ▲ +81.9% | — |
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Distribution yield and SEC yield use different methodologies. Payouts may include income, capital gains, or return of capital.
| Ex-date | Pay date | Per share |
|---|---|---|
| 2024-12-19 | 2024-12-26 | $1.17 |
| 2023-12-21 | 2023-12-27 | $0.07 |
| 2019-12-19 | 2019-12-27 | $0.02 |
| 2018-12-20 | 2018-12-27 | $0.78 |
| 2017-12-21 | 2017-12-28 | $0.58 |
Estimated annual expense excludes trading costs and assumes constant assets. Fee waivers and fund costs can change.
Historical risk measures describe past behavior and do not predict future returns.
Hear the strategy from the people behind SBIO.